Joseph J. Barchi Jr., Ph.D.

Joseph J. Barchi Jr., Ph.D.
Senior Scientist
Head, Structural Glycoconjugate Chemistry and NMR Group

Dr Barchi’s career at the NCI has spanned a wide breadth of drug discovery efforts, including the synthesis of PKC and reverse transcriptase inhibitors, the development of glycopeptide antigens as vaccine candidates against HIV and cancer, as well as the discovery of several glycopeptide-analogues of Antiproliferative Factor (APF), a negative growth factor isolated from patients with interstitial cystitis. Current focus in the lab is the discovery of novel nanoplatforms for the delivery and therapeutic applications of immunogenic glycopeptides, the search for selective antitumor agents based on APF and the conformational analysis of these synthetic analogues by NMR spectroscopy to guide further discovery efforts.

Link to additional information about Dr. Barchi's research.

Areas of Expertise
1) Synthetic Organic Chemistry 2) Carbohydrate/Glycoscience 3) Small Molecule NMR Spectroscopy

Contact Info

Joseph J. Barchi Jr., Ph.D.
Center for Cancer Research
National Cancer Institute
Building 376, Room 209
Frederick, MD 21702-1201
Ph: 301-846-5905
Fax: 301-846-6033

1. Multivalent Presentation of Tumor-Associated Carbohydrate Antigens (TACA) and TACA-Peptide Conjugates as Novel Anticancer Agents

Carbohydrates are presented on the surface of cells primarily in covalent linkages to proteins (glycoproteins, proteoglycans) or lipids (glycolipids, gangliosides). These diverse groups of oligosaccharide chains function to stabilize protein structures, facilitate protein transport or clearance, and mediate cell adhesion. Cell-surface glycans may reveal or mask peptide epitopes on proteins or be recognized as immunogenic structures themselves. During oncogenesis, the cell-surface glycans on tumor cells are transformed relative to the normal phenotype through modified expression of the enzymes involved in the cell's glycoprocessing machinery. These aberrations are a hallmark of highly tumorigenic and metastatic cell types. The cascade of events leading to tumor metastasis is marked by the alternate adhesion and release of the tumor cell with a variety of surrounding cell types. The binding between tumors and other cell types is often mediated by carbohydrate-protein (lectin) interactions involving the aberrant glycans expressed on tumor cells. Inhibition of these adhesion events could slow or prevent metastatic spread. In addition, some of these tumor cell glycans are TACA's that are recognized as non-self by the immune system and have thus been used as components in vaccine constructs that are in clinical trials. Since it is well known that monovalent sugar-protein binding is a very weak interaction, inhibitors of these events utilize 'multivalency' (multiple copies of the carbohydrate ligand) to enhance the strength of this effect.

We are exploring ways to synthesize novel templates on which to place multiple copies of the Thomsen Freidenreich (TF) antigen, a disaccharide O-linked to proteins found on the cell surface that is present in >90% of carcinomas but rarely found in normal tissue. We have developed a new synthesis of this antigen that is equipped with a chemically-defined specific linker to attach to macromolecules or other surfaces. We have coated the TF antigen to gold surfaces and Quantum Dots (QDs) in a variety of different presentations (simple linked TF, TF-amino acid conjugates and larger TF-containing glycopeptides) and showed that some of these construct have very interesting biological functions. In addition, our group developed an hybrid gold nanoparticle that can act as a vaccine delivery system for tumor-associated glycopeptide antigens. Our goal is to optimize these various nanoconstructs to enhance a glycopeptide-specific immune response that will be specific for distinct tumors bearing these antigens.

2. Antiproliferative Factor (APF): A novel antiproliferative glycopeptide from interstitial cystitis/bladder pain syndrome (IC/BPS) patients.

IC/BPS is a devastating bladder disorder characterized by frequency, urgency and severe pain,. A novel glycopeptide called APF was isolated from the urine of IC/BPS patients by the team of Susan Keay at the University of Maryland and and fully characterized and synthesized in our lab. APF treatment of normal bladder epithelial cells inhibits proliferation at sub-nanomolar concentrations, and imparts many features to these cells as seen in the actual disease. In addition, APF inhibits proliferation of bladder carcinoma and many other solid tumor cells at similar concentrations. We are presently synthesizing analogues of APF and have defined a structure activity relationship for the molecule. We are exploring analogues that may inhibit proliferation as treatments for IC/BPS or mimic APF activity with specificity for tumors as anticancer agents. Chemical biology techniques are being employed to study the biosynthesis and structural basis for the activity of this novel glycopeptide.

3. Conformational analysis of small molecules by NMR

Along with our group, The entire CBL synthesizes small molecule agents as potential anticancer or antiviral therapeutics. Our section uses NMR spectroscopy to determine 3-dimensional conformations of many of these candidates as an aid to structure-based drug design. Currently, a major area of research has focused on the different conformations imparted to peptides by various covalently linked TACAs/sugars. We discovered a distinct difference between the structures of glycosylated serine versus threonine---Serine-conjugated sugars are relatively free to explore the conformational space whereas threonine-coupled sugars are much more restricted. We are studying the biological consequences of these preferences in the context of different sugar-binding proteins.

Scientific Focus Areas:
Chemical Biology, Immunology, Structural Biology
  1. Synthesis and Cell-Selective Antitumor Properties of Amino Acid Conjugated Tumor-Associated Carbohydrate Antigen-Coated Gold Nanoparticles.
    Biswas S, Medina S, and Barchi Jr JJ
    Carbohydrate Res. In press: Elsevier 2014. [ Journal Article ]
  2. Carbohydrate Nanotechnology and its Applications for the Treatment of Cancer.
    Ambre S and Barchi Jr JJ
    In: Carbohydrate Nanotechnology. In press: Hoboken, NJ: Wiley 2015. [ Book Chapter ]
  3. Glinskii OV, Li F, Wilson LS, Barnes S, Rittenhouse-Olson K, Barchi Jr JJ, Pienta KJ, Glinsky VV
    Oncotarget. 5: 1382-1389, 2014. [ Journal Article ]
  4. Luo M, Velikovsky CA, Yang X, Siddiqui MA, Hong X, Barchi JJ, Gildersleeve JC, Pancer Z, Mariuzza RA.
    J. Biol. Chem. 288: Am. Society for Biochemistry and Molecular Biology 23597-23606, 2013. [ Journal Article ]
  5. Barchi Jr JJ
    Biopolymers. 99: John Wiley and American Peptide Society 713-723, 2013. [ Journal Article ]

Dr. Barchi received his Ph.D. in Organic Chemistry from the University of Hawaii with Richard E. Moore and did 2 years of postdoctoral work at Duke University with Bert Fraser-Reid. He then joined the NCI as a staff fellow in 1988, was promoted to staff scientist and then to senior scientist in 2002. His main research interests are in synthetic medicinal chemistry as it relates to carbohydrate-based drug design, and the high-resolution structural analysis of sugars, glycopeptides and small molecule drug candidates by NMR spectroscopy.

Name Position
James Collin Hickey Special Volunteer
Maqbool Siddiqui M.S. Research Chemist
Kevin Trabbic Ph.D. Postdoctoral Fellow (CRTA)